Table 2.
Medical History, Medications and Management of COPD Before the COVID-19 Epidemic
| Variables | Median [25th, 75th Percentiles] or N (%) |
|---|---|
| History of COPD (year) | 5.0 [3.0, 8.0] |
| Exacerbation in the past year | |
| Frequency of exacerbation (/year) | |
| 0 | 129 (84.3) |
| 1 | 17 (11.1) |
| ≥2 | 7 (4.6) |
| Hospitalization due to exacerbation | |
| 0 | 135 (88.2) |
| ≥1 | 18 (11.8) |
| Pharmacological treatment | |
| Inhaled SABA | 6 (3.9) |
| Inhaled SAMA | 2 (1.3) |
| ICS/LABA | 93 (60.8) |
| LAMA | 88 (57.5) |
| Oral theophylline | 12 (7.8) |
| Non-pharmacological management and health behavior | |
| Ever attending any education sessions | 23 (15.0) |
| Ever consulting respiratory specialists online | 3 (2.0) |
| Having a long-term personalized action plan | 22 (14.4) |
Note: Data are presented as median [25th, 75th percentiles] or n (%).
Abbreviations: COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist.